Search

Ocugen Inc

Cerrado

1.01

Resumen

Variación precio

24h

Actual

Mínimo

1.01

Máximo

1.04

Métricas clave

By Trading Economics

Ingresos

-5.7M

-25M

Ventas

-45K

1.5M

BPA

-0.07

Margen de beneficios

-1,671.841

Empleados

116

EBITDA

-2.5M

-20M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+892.65% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-67M

349M

Apertura anterior

1.01

Cierre anterior

1.01

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 sept 2026, 23:56 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

25 sept 2026, 23:55 UTC

AtriCure Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average despite retracing some initial gains.

25 sept 2026, 23:55 UTC

Wendy's Co saw modest gains during after-market hours on Friday, continuing its upward movement but remaining below its 20-day moving average.

25 sept 2026, 23:55 UTC

Lexicon Pharmaceuticals Inc is rising in after-market trading, gaining ground since Friday's close, marking a notable divergence from four consecutive sessions of losses.

25 sept 2026, 23:55 UTC

Cognizant Technology Solutions Corp is trading modestly higher in after-market hours, reaching a peak return since Friday's close, despite remaining below its 20-day moving average.

25 sept 2026, 23:51 UTC

Hamilton Beach Brands Holding Co has advanced in after-market trading, significantly above its 20-day moving average and near the upper end of its one-month range.

25 sept 2026, 23:51 UTC

Social Media

Darden Restaurants Inc reported a rise in sales to $3.2 billion, but net income fell, leading to a decline in stock price in after-market trading.

25 sept 2026, 23:51 UTC

News

CDW Corp completed its acquisition of Lovelytics, enhancing its Services and Solutions portfolio, as shares advanced in after-market trading.

25 sept 2026, 23:51 UTC

Krispy Kreme Inc is advancing in after-market trading, showing a notable increase since Friday's close, despite being below its 20-day moving average.

25 sept 2026, 23:51 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, reflecting a notable decline since Friday's close and today's sharp loss.

25 sept 2026, 23:51 UTC

News

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

25 sept 2026, 23:51 UTC

Southern Co is trading slightly higher in after-market hours, though its price remains below the 20-day moving average after four consecutive lower closes.

25 sept 2026, 23:51 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to reflect cautious market sentiment amid agricultural sector challenges and external economic pressures.

25 sept 2026, 23:51 UTC

S&P/Case-Shiller Index Forecasts 2.2% Year-over-Year Home Price Increase Amid Mixed Housing Sentiment and Rising Treasury Yields

25 sept 2026, 23:51 UTC

South Korea's S&P Global Manufacturing PMI set for October 1 release amid slowing growth and geopolitical tensions impacting market sentiment.

25 sept 2026, 23:50 UTC

Southern Missouri Bancorp Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and near the lower end of its one-month range.

25 sept 2026, 23:50 UTC

Upstart Holdings Inc is trading modestly higher in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

25 sept 2026, 23:50 UTC

ABM Industries Inc is down in after-market trading, moving from a slight dip to a more pronounced decline since Friday's close.

25 sept 2026, 23:50 UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

25 sept 2026, 23:50 UTC

Ambarella Inc is rising in after-market trading, continuing its positive trend and remaining significantly above its 20-day moving average.

25 sept 2026, 23:50 UTC

Recursion Pharmaceuticals Inc has advanced in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month trading range.

25 sept 2026, 23:50 UTC

Etsy Inc. has advanced in after-market trading, despite a notable decline from its earlier high and positioning below its 20-day moving average.

25 sept 2026, 23:50 UTC

Baker Hughes Co is trading modestly higher in after-market hours, showing unusual upward movement despite remaining below its 20-day moving average.

25 sept 2026, 23:50 UTC

Altria Group Inc is experiencing a slight increase in after-market trading, advancing since Friday's close despite some unusual activity and price retracement.

25 sept 2026, 23:50 UTC

Medtronic PLC is down in after-market trading, continuing a seven-session trend of lower finishes and remaining significantly below its 20-day moving average.

25 sept 2026, 23:50 UTC

Tencent Music Entertainment Group declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above its 20-day moving average.

25 sept 2026, 23:46 UTC

Parker-Hannifin Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

25 sept 2026, 23:46 UTC

Northern Oil and Gas Inc is trading modestly higher in after-market hours, reaching a peak return since Friday's close, though still below its 20-day moving average.

25 sept 2026, 23:46 UTC

Modest increase in after-market trading, peak return near 0.9%.

25 sept 2026, 23:46 UTC

Correlated Moves

Alaska Air Group Inc's shares are trading roughly flat in after-market hours, reflecting routine activity amid slight gains in the Fidelity Enhanced Small Cap Core ETF.

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

892.65% repunte

Estimación a 12 Meses

Media 10.125 USD  892.65%

Máximo 12 USD

Mínimo 8 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.